as declared in news-medical
Survey finds seven out of ten cancer patients receive palliative care consultation at ESMO Designated Centres
Survey finds seven out of ten cancer patients receive palliative care consultation at ESMO Designated Centres
Seven out of ten patients with advanced cancer receive a palliative care consultation at ESMO Designated Centres of Integrated Oncology and Palliative Care, according to survey results reported today at the ESMO 2016 Congress in Copenhagen.The news comes as the Designated Centre distinction is awarded to 142 centres this year, bringing the total to 200 from 42 countries.3 Nine Palliative Care Fellowships4 will also be bestowed, providing an intensive period of observation or research at an ESMO Designated Centre.The ESMO Designated Centres programme is the premier initiative worldwide championing integrated programmes in oncology and palliative care, aiming to ease the physical and mental suffering of cancer patients during anticancer treatment and also at the end of life.Since 2003 the distinction has recognised cancer centres that achieve a high standard of integration of medical oncology and palliative care.5 The designation is valid for three years and in 2016 some 74 centres are due to re-accredit, of which seven joined the programme in 2003.
as well news-medical
Immunotherapy redefines treatment approach for metastatic bladder cancer patients
Immunotherapy redefines treatment approach for metastatic bladder cancer patients
Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.Up to half of patients with metastatic bladder cancer are not eligible for survival prolonging first line treatment with cisplatin-based chemotherapy.Survival in these patients is just nine to ten months with currently available alternative chemotherapy.The phase II KEYNOTE-052 trial1 evaluated the efficacy and safety of PD-1 blockade with pembrolizumab as first line therapy in cisplatin ineligible patients with metastatic or locally advanced bladder cancer.
coupled with news-medical
PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer
PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine (NEJM).The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo."There are limited treatment options in recurrent ovarian cancer," said lead author Dr Mansoor Raza Mirza, chief oncologist, Rigshospitalet, Copenhagen University Hospital, Denmark and medical director of the Nordic Society of Gynaecological Oncology (NSGO)."Cumulative toxicity with platinum-based chemotherapy and lack of additional benefit limits its use.
No comments:
Post a Comment